A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry.
To determine a phenotypic difference between normal endometrium and endometrial adenocarcinoma, a new monoclonal antibody (MSN-1) was produced by immunizing a new endometrial cancer cell line (SNG-II), which was established in 1981 from a 43-year-old Japanese woman with stage II uterine endometrial cancer. MSN-1 recognized the Lewis-b carbohydrate moiety on the cell surface glycolipid and seldom reacted immunohistochemically with normal endometrium but with about 90% of endometrial cancer cases. By application of MSN-1 to flow cytometry, the possibility of differentiating endometrial normal cells from cancer cells was demonstrated.
Nozawa
S
S
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Sakayori
M
M
Ohta
K
K
Iizuka
R
R
Mochizuki
H
H
Soma
M
M
Fujimoto
J
J
Hata
J
J
Iwamori
M
M
Nagai
Y
Y
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis; D000939:Epitopes; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D007621:Karyotyping; D009367:Neoplasm Staging; D011003:Ploidies; D014407:Tumor Cells, Cultured; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000235:genetics
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000939:Epitopes